Newswise Curated News Channel: Medical Meetings

Discovery of Gene Linked to High-Altitude Adaptation May Transform Blood Cancer Care

Huntsman Cancer Institute at the University of Utah — Thu, 12 Dec 2024 21:00:38 EST

Huntsman Cancer Institute researchers have identified a gene variant found in a high-altitude Andean population that may predict severity of diseases and responses to treatments for patients with certain types of blood cancer.

Lurie Children's Diabetes Program Receives 2024 T1D Exchange Outstanding Pediatric Team Award

Ann and Robert H. Lurie Children's Hospital of Chicago — Tue, 10 Dec 2024 12:00:34 EST

In November, Lurie Children's and Northwestern University co-hosted the 2024 T1D Exchange Learning Session in Chicago. The T1D Exchange Quality Improvement Collaborative (QIC) brings together clinics across the United States, connecting experts that collectively treat over 100,000 individuals with Type 1 diabetes.

SABCS: Improved Survival for Advanced Breast Cancer, Using Genomics to Identify Patients with High Risk of Recurrence, How Race/Ethnicity Influence the Risk of Heart Failure in Early-Stage Breast Cancer and More

University of California, Los Angeles (UCLA), Health Sciences — Tue, 10 Dec 2024 11:00:47 EST

The UCLA team will be presenting original research related to novel therapeutics, functional imaging, immunotherapy-related complications, socioeconomic disparities, and genomic interception strategies for patients with high risk for breast cancer recurrence.

EMBARGOED: Dozens of Presentations Advance Multiple Myeloma Research at the 2024 American Society for Hematology (ASH) Meeting

Sylvester Comprehensive Cancer Center — Mon, 09 Dec 2024 21:00:00 EST

Patients with multiple myeloma are living longer thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center are working to change that, and will present research findings at the 2024 annual meeting of the American Society of Hematology (ASH).

ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

University of Texas MD Anderson Cancer Center — Mon, 09 Dec 2024 20:00:38 EST

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH

Roswell Park Comprehensive Cancer Center — Mon, 09 Dec 2024 19:30:00 EST

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.

ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory Disorder

University of Texas MD Anderson Cancer Center — Mon, 09 Dec 2024 17:45:42 EST

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) - a rare, aggressive hyperinflammatory condition - who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows

Roswell Park Comprehensive Cancer Center — Sun, 08 Dec 2024 16:30:07 EST

Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.

Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma

Roswell Park Comprehensive Cancer Center — Sun, 08 Dec 2024 12:30:00 EST

The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.

ASH 2024: Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma

Sylvester Comprehensive Cancer Center — Sun, 08 Dec 2024 12:00:00 EST

ASH 2024 Presentations: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers - follicular lymphoma and marginal zone lymphoma.

Multi-Center Study Shows Education Level, Income Impact Access to Stem Cell Transplantation for Acute Myeloid Leukemia Patients

Fred Hutchinson Cancer Center — Sun, 08 Dec 2024 11:10:31 EST

Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive a allogeneic hematopoietic stem cell transplant for acute myeloid, however, if they can access the treatment, are equally likely to benefit from transplant as patients with more education and higher income, according to a new study from Fred Hutch Cancer Center presented at the annual meeting of the American Society of Hematology.

Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias

Roswell Park Comprehensive Cancer Center — Sat, 07 Dec 2024 19:00:24 EST

A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates -- FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.

Keto Diet Metabolite May Power Up CAR T Cells to Kill Cancer

Perelman School of Medicine at the University of Pennsylvania — Sat, 07 Dec 2024 10:15:00 EST

A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center, presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 4).

New Research from Children's Hospital of Philadelphia to Transform Standard of Care Across the Globe for Newly Diagnosed Children with B-cell Acute Lymphoblastic Leukemia

Children's Hospital of Philadelphia — Sat, 07 Dec 2024 10:00:32 EST

Researchers at Children's Hospital of Philadelphia (CHOP) and the Children's Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.

Cedars-Sinai Pharmacists Attending Midyear Clinical Meeting 2024

Cedars-Sinai — Fri, 06 Dec 2024 23:10:17 EST

Cedars-Sinai experts in pharmacy services attending the Dec. 8-12 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting 2024 in New Orleans are available for interviews about the latest developments in patient safety and pharmacy practice.

HKIAS Annual General Meeting 2024: Fostering Global Collaboration and Celebrating Excellence

Hong Kong Institute for Advanced Study, City University of Hong Kong — Fri, 06 Dec 2024 03:40:12 EST

The Hong Kong Institute for Advanced Study (HKIAS) hosted its Annual General Meeting (AGM) on 19 November 2024, bringing together Senior Fellows from across the globe to discuss strategic advancements in research and international collaboration. Chaired by our HKIAS Chairman Professor Serge Haroche, the meeting focused on strengthening global partnerships between the City University of Hong Kong (CityUHK) and the home institutions of our Senior Fellows, recruiting leading scholars to HKIAS, and preparing for the Institute's 10th-anniversary celebration in 2025, etc.

Drug Offers Cost-Effective Protection for Newborns with Genetic Bleeding Disorder

Yale Cancer Center/Smilow Cancer Hospital — Thu, 05 Dec 2024 14:10:04 EST

Severe hemophilia A is a genetic disorder that prevents blood from clotting properly, posing a constant risk of dangerous bleeding episodes. Infants with severe hemophilia A (HA) are at risk of brain bleeds, which can lead to serious long-term brain damage. Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A.

Late-Breaking Abstract at SUO: Novel Oncolytic Immunotherapy Shows Promise for Patients with Bladder Cancer

Mayo Clinic — Thu, 05 Dec 2024 12:50:00 EST

A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of Urologic Oncology Annual Meeting. The study demonstrated a potentially effective treatment for patients with bladder cancer who no longer respond to the common therapy, Bacillus Calmette-Guerin (BCG).

Tip Sheet: New Insights on RSV and Malaria, Metastatic Breast Cancer Resources for Patients -- and Fred Hutch at ASH

Fred Hutchinson Cancer Center — Thu, 05 Dec 2024 09:00:27 EST

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.

MD Anderson Research Highlights: ASH 2024 Special Edition

University of Texas MD Anderson Cancer Center — Wed, 04 Dec 2024 12:00:04 EST

The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features upcoming oral presentations by MD Anderson researchers at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, providing new insights and advances in hematological malignancies and diseases. All ASH content from MD Anderson can be found at MDAnderson.org/ASH.